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Abstract


The thesis entitled “Stereoselective Synthesis of C6-Substituted Furanoid Sugar Amino Acids, Synthesis and Conformational Studies of Peptidomimetics Containing Sugar Amino Acids and the Total Synthesis of Conagenin” consists of three chapters:

CHAPTER I: Deals with the synthesis of C6-substituted furanoid sugar amino acids. This chapter is divided into three parts: PART-A: deals with the stereoselective synthesis of C6-substituted 3,4-dideoxy furanoid sugar amino acids; PART-B: concerns with the stereoselctive synthesis of the various isomers of 3,4-dideoxy furanoid sugar amino acids with methyl substitution at the C6 position; PART-C: describes the synthesis of furanoid sugar amino acid with methyl substitution at the C6 position.

CHAPTER II: Describes the synthesis and conformational studies of peptidomimetics containing sugar amino acids.

CHAPTER III: Describes the total synthesis of Conagenin.

                                                               CHAPTER I

PART-A: Stereoselective Synthesis of C6-Substituted 3,4-Dideoxy Furanoid Sugar Amino Acids
Emulating the basic principles followed by nature to build its vast repertoire of biomolecules, organic chemists are developing many novel multifunctional building blocks to construct peptides that mimic the ordered secondary structures displayed by the biopolymers and their functions. Rationally chosen monomeric units from the large number of structurally diverse designed building blocks are woven together in specific sequence by iterative synthetic methods leading to the development of novel            homo-polymers and hetero-polymers with architecturally beautiful 3D structures and desirable properties. Sugar amino acids constitute an important class of such polyfunctional scaffolds where the carboxyl, amino and hydroxyl termini provide an excellent opportunity to organic chemists to create structural diversities akin to nature’s molecular arsenal. The rigid furanoid or pyranoid rings of these molecules make them ideal candidates as non-peptide scaffolds in peptidomimetic studies where they can easily be incorporated by using their carboxyl and amino termini utilizing well-developed   solid-phase or solution-phase peptide synthesis methods. At the same time, it allows an efficient exploitation of the structural diversities of carbohydrate molecules to create combinatorial library of sugar amino acid-based molecular frameworks predisposed to fold into architecturally beautiful ordered structures which may also have interesting properties. The protected/unprotected hydroxyl groups of sugar rings can also influence the hydrophobic/hydrophilic nature of such molecular assemblies.
Inspired by those salient features of sugar amino acids, literature survey and ultimately our thrust towards developing new methods in organic synthesis, prompted us to endeavor towards the synthesis of C6-substituted furanoid sugar amino acids 1a-d (Figure 1) in which presence of several chiral centers can gives rise to large number of possible isomers.

        Figure 1	
Synthesis of C6-substituted sugar amino acids 1a-d comes under one general scheme. Our synthesis was started with nucleophilic addition of an anion, generated from 3,4-O-isopropylidene-1,1-dibromobut-1-en-3,4-diol 2, to (S)-N,N-dibenzylamino aldehyde 3a-d. The dibromo compound 2 was obtained quantitatively from                  (R)-glyceraldehyde acetonide, which could be made by oxidative cleavage of 1,2:5,6-di-O-isopropylidene-D-mannitol using NaIO4, following the reported procedure. Then    N,N-dibenzylaminoaldehydes 3a-d were also prepared accordingly as directed in literature. The reaction was carried out at –78 ºC for 30 minutes and at room temperature for another 30 minutes, then aldehydes 3a-d were added at –78 ºC and raised to room temperature. The yields of the products 4a-d were 78-93% (Scheme 1).


Scheme 1
	
Compounds 4a-d were subjected to hydrogenation in the presence of Pd(OH)2/C in a mixture of MeOH and EtOAc to give saturated and debenzylated free amine that was protected with Boc2O in the presence of Et3N in MeOH to get compounds 5a-d in         83-92% yield. Deprotection of acetonide group of compounds 5a-d with CSA in MeOH at 0 ºC gave triol products 6a-d in 85-95% yield. 
Selective sulfonylation of the primary hydroxyl group of 6a-d with 2,4,6-triisopropylbenzenesulfonyl chloride in the presence of pyridine in CH2Cl2 gave sulfonate intermediate that was treated with K2CO3 in MeOH to get the tetrahydrofuran frameworks 7a-d in 72-88% yield (Scheme 2).


Scheme 2
Finally, a two-step oxidation process converted the primary hydroxyl group of      7a-d into an acid that was treated with an excess of diazomethane in ether to give the target molecules 1a-d in 84-88% yield.


PART-B: Stereoselctive Synthesis of the Various Isomers of 3,4-Dideoxy Furanoid Sugar Amino Acids with Methyl Substitution at the C6 Position
To demonstrate the versatility of the method described above, we employed it successfully for the synthesis of six isomers of 3,4-dideoxy furanoid sugar amino acids with methyl substitution at the C6 position of 1a, 8-12 (Figure 2).


                                                       Figure 2 
The starting materials for the synthesis of compounds 1a and 8 were L-alanine-derived amino aldehyde 3a and compound 2. Synthesis of compound 1a was out lined in Schemes 1 & 2. The isomer 8 was started from inverting the free hydroxyl group of 4a by oxidation-reduction sequence (Scheme 3). Treatment of 4a with SO3-Py complex in the presence of Et3N in a mixture of CH2Cl2 and DMSO at 0 ºC afforded unstable keto intermediate that was immediately reduced diasteroselectively by using K-Selectride at    –78 ºC in THF to give compound 13 in 75% yield in two steps. Compound 13 was then transformed into furanoid 3,4-dideoxy sugar amino acid (2R,5S,6S)-8 (48% overall yield from 13) following the same procedure as described for the synthesis of 1a. 


Scheme 3

For the synthesis of compounds 9 and 10, L-alanine-derived N,N-dibenzylamino aldehyde 3a was reacted with the Li-acetylide, generated from 17. Compound 17, an enantiomer of 2, was prepared from L-ascorbic acid following the reported procedure. The adduct 18, formed in 89% yield exclusively with no trace of other diastereomer, was converted to 19 in 82% yield by the same oxidation-reduction sequence used for the synthesis of 13. Compounds 18 and 19 were next transformed into the furanoid 3,4-dideoxy sugar amino acids  (2S,5R,6S)-9 (51% overall yield from 18) and (2S,5S,6S)-10 (52% overall yield from 19), respectively (Scheme 4), following the same procedure as described for the synthesis of 1a.


        Scheme 4
Syntheses of isomers 11 and 12 were carried out by reacting D-alanine-derived N,N-dibenzylamino aldehyde 20 with the Li-acetylide of 17 and 2 to give adducts 21 and 22 respectively, in 89% yield. These adducts 21 and 22 can be transformed into the furanoid 3,4-dideoxy sugar amino acids (2S,5S,6R)-11 and (2R,5S,6R)-12 in 51% overall yield, respectively (Scheme 5), following the same procedure as described for the synthesis of 1a.

                                                            Scheme 5

PART-C: Synthesis of Furanoid Sugar Amino Acid with Methyl Substitution at the C6 Position
	Having synthesized successfully the 3,4-dideoxy furanoid sugar amino acids derived from different α-amino acids and various isomers of the alanine-derived sugar amino acids, we were motivated to  focus our attention on the synthesis of hydroxylated C6-substituted furanoid sugar amino acid 23 (Figure 3). 

   Figure 3

	The synthesis of compound 23 was started from the partial hydrogenation of alkyne group of 18 using Pd-C/BaSO4 as catalyst in hexane that gave the cis alkene 24 in 79% yield (Scheme 6). Deprotection of acetonide moiety of 24 was carried out by treating it with CSA in MeOH to give triol 25 in 94% yield. Primary hydroxyl group of 25 was treated with TrisCl in the presence of pyridine in CH2Cl2 to give selective mono-sulfonate intermediate that was converted to compound 26 in 77% yield by treating with K2CO3 in MeOH. Treatment of 26 with catalytic amount OsO4 in the presence of NMO in a mixture of acetone and H2O afforded syn hydroxylated compound 27 in 94% yield.

   Scheme 6

Hydrogenation of the compound 27 in the presence of catalytic amount of Pd(OH)2/C in MeOH resulted free amine that was protected using  Boc2O in basic condition to give compound 28 in 88% yield. Selective acetonide protection of two secondary hydroxyl groups of 28 using 2,2-DMP in the presence of catalytic amount CSA in acetone gave compound 29 in quantitative yield. Finally, oxidation of the primary hydroxyl group of 29 using catalytic amount of TEMPO and tBuOCl in basic condition converted it into an acid that was treated with an excess of CH2N2 in ether to give the requisite product 23 in 81% yield (Scheme 7). 

Scheme 7

In conclusion, we have demonstrated the synthesis of different C6-substituted sugar amino acids following the common strategy. 

CHAPTER-II
Synthesis and Conformational Studies of Peptidomimetics Containing Sugar Amino Acids
	For discovering new peptide-based drugs, many structurally rigid nonpeptidic molecular scaffolds have been designed. Insertion of these moieties in appropriate sites, a common approach to restrict the conformational degrees of freedom in peptides, produces the specific three-dimensional structures required for binding their receptors. Many of these templates containing sugar amino acids have been used extensively as conformationally constrained scaffolds in many peptidomimetic studies.
	Herein we have undertaken the design of the peptidomimetic analogs of a known antagonist of vasoactive intestinal peptide (VIP), which is a widely distributed naturally occurring neuropeptide with wide ranging biological activities. The invitro studies suggest that VIP acts as a growth factor and plays a dominant role in the sustained or indefinite proliferation of cancer cells. The peptide sequence Leu1-Met2-Tyr3-Pro4-Thr5-Tyr6-Leu7-Lys8 1 (Figure 1) is known to be one such VIP receptor binding inhibitor and also has the potential to arrest the growth of malignant cells. 

                                                       

Figure 1

The design of the peptidomimetic analogs of 1 could be greatly facilitated by the knowledge of its 3D-structure. So we carried out structural studies of the octapeptide 1 using various NMR techniques that established a well-defined turn structure involving Tyr3-Pro4-Thr5-Tyr6 residues. Based on these structural studies, novel peptidomimetic analogs 7, 7a, 8, 8a, 9, 9a, 10 and 11 were subsequently developed using various furanoid sugar amino acids 2-6 (Figure 2).

Figure 2
	Insertion of sugar amino acids (2S,5R)-2 and its enantiomer (2R,5S)-3 as dipeptide isosters in place of the Tyr3-Pro4 segment of 1 led to the formation of the analogs 7 and 7a, respectively (Figure 3). Incorporation of sugar amino acid 4, racemic mixture of 2 and 3, into the octapeptide 1 by replacing Tyr3-Pro4 and Pro4-Thr5 gave diastereomeric mixture of products 7, 7a and 8, 8a, respectively. These diastereomers were separated by HPLC. 

Figure 3
The HPLC purified diastereomeric peptides, obtained here by insertion of 4 into 1 by replacing Tyr3-Pro4, were matched with the peptides 7 and 7a, obtained from insertion of enantiomerically pure sugar amino acids 2 and 3. Further truncation of 1, replacing three of its amino acids Tyr3-Pro4-Thr5 with 2, 4 and deleting one residue each from both the termini, gave analog 9 and diastereomeric mixture of products 9 and 9a, respectively (Figure 3). However these diastereomeric mixture of products 9 and 9a could not be separated by HPLC. 
We also synthesized analogs of the pentapeptide Met-Pro-Thr-Tyr-Leu-OH, derived from octapeptide 1, replacing its Pro-Thr dipeptide segment with 5 to get the peptide 10 (Figure 4). Furan sugar amino acid 6 has been used to replace Pro4-Thr5 in the octapeptide 1 sequence to generate the more hydrophobic peptide analog 11.

                     Figure 4
The synthesis of furanoid sugar amino acids, starting materials for the peptide analogs of 1, was described in Scheme 1-3. The starting material for the synthesis of Fmoc-protected 2 was furan carboxylic acid 13, which was prepared from L-glutamic acid 12 in 66% yield, following the reported procedure. The compound 13 was converted to alcohol 14 in 78% yield by treating with borane-dimethyl sulfide complex in THF at 0 ºC to room temperature. The primary hydroxyl group of 14 was protected as trityl ether by using trityl chloride, pyridine and catalytic amount of DMAP to give 15 in 77% yield. The lactone 15 was reduced with DIBAL-H in CH2Cl2 to afford 16 as a mixture of diastereomers at anomeric position in 86% yield. Acetylation of lactol hydroxyl group of 16 using Ac2O, Et3N and catalytic amount of DMAP gave a glycosyl acetate compound 17 in 96% yield. Treatment of the compound 17 with trimethylsilyl cyanide in the presence of BF3-Et2O afforded diastereomeric mixture of glycosyl cyanide alcohols 18 in 64% yield. Reduction of the cyanide group of 18 was carried out by refluxing with LiAlH4 in ether to furnish the diastereomeric mixture of free amino alcohol that was protected using FmocOSu to give 19 in 57% yield and the other isomer. Finally, the primary hydroxyl group of 19 was oxidized to an acid Fmoc-2 in 67% yield using Jones’ reagent (Scheme 1).  

             Scheme 1
Synthesis of the enantiomer of Fmoc-2, Fmoc-3, was started with the known compound 20, which was prepared from D-glucose following the reported procedure. Hydrogenation of 20 using Pd(OH)2/C as a catalyst in MeOH gave benzyl deprotected compound 21 in 95% yield. Selective silylation of the primary hydroxyl group of 21 using TBDPSCl, Et3N, and catalytic amount of DMAP gave 22 in 96% yield. Treatment of diol 22 with Ph3P/I2/imidazole in reflux toluene led to the formation of an olefinic compound 23 in 85% yield. Olefin compound 23 was subjected to hydrogenation using Pd(OH)2/C as catalyst in MeOH to furnish 24 in 93% yield. Compound 24 was transformed into 25 in 85% yield by using TBAF in THF. Compound 25 was transformed into the required Fmoc-protected product 3 following a three-step process-oxidation of the primary hydroxyl to get the carboxylic acid 26, Boc-deprotection using TFA in CH2Cl2, followed by Fmoc protection using FmocOSu to furnish Fmoc-3 in 68% yield in three steps (Scheme 2).  All the spectral data of Fmoc-3 are in an agreement with Fmoc-2 except rotation which is equal in magnitude but opposite in sign, indicating that both are enantiomers.

Scheme 2

Fmoc- 4, racemic mixture of Fmoc-2 and 3, can easily be prepared from the    Boc-protected compound 5 which was prepared from D-fructose following the reported procedure. Hydrogenation of Boc-5 using Pd(OH)2/C as a catalyst in MeOH gave saturated furanoid sugar amino acid Boc-4 in 91% yield. Finally, compound Boc-4 was converted to Fmoc-4 in 79% yield in two steps (Scheme 3), following the same procedure as described for the synthesis of Fmoc-3. The other sugar amino acid 6 was prepared from D-mannitol following the reported procedure.


Scheme 3

The various sugar amino acids were then used to prepare our target peptidomimetic analogs of 1. The peptides were prepared by solid phase peptide synthesis method. 
Conformational analysis of peptide 1, 7, 7a and 9 were carried out in DMSO-d6 by extensive NMR studies including TOCSY and ROESY experiments and molecular dynamics (MD) studies. Variable temperature studies were carried out to measure the temperature coefficients of the amide proton chemical shifts (Δδ/ΔT), which provided information about their involvements in intramolecular hydrogen bonds. The detailed NMR studies in DMSO-d6 and subsequent constrained MD simulations revealed that the peptide 1 has 10-membered type-II β-turn around Pro4-Thr5residue (Figure 5). 

Figure 5: Stereo view of the 25 superimposed energy-minimized structure 1 sampled during 50 cycles of the 300 ps constrained MD simulations following the simulated annealing protocol: H-bonded region (left), full structure (right) 

	Peptide 7 shows the existence of a 10-membered hydrogen bonded turn structure between ThrNH→MetCO, which mimics a regular β-turn structure, where as the rest of the peptide backbone seems to take an extended conformation (Figure 6). 
Figure 6: Stereo view of the 25 superimposed energy-minimized structure 7 sampled during 50 cycles of the 300 ps constrained MD simulations following the simulated annealing protocol: H-bonded region (left), full structure (right) 

	In compound 7a the observed β-turn conformation of the peptide is similar to that of 7. MD calculations showed the existence of a 10-membered H-bond between ThrNH→MetCO (Figure 7).                                                                          

Figure 7: Stereo view of the 25 superimposed energy-minimized structure 7a sampled during 50 cycles of the 300 ps constrained MD simulations following the simulated annealing protocol: H-bonded region (left), full structure (right) 

In compound 9, TyrNH shows small magnitude of Δδ/ΔT (–2.8 ppb/ºK), indicating its participation in intramolecular hydrogen bonding. The MD calculations showed the existence of a β-turn like structure having a 10-membered intramolecular hydrogen bond (Figure 8).
Figure 8: Stereo view of the 25 superimposed energy-minimized structure 9 sampled during 50 cycles of the 300 ps constrained MD simulations following the simulated annealing protocol: H-bonded region (left), full structure (right) 
	In conclusion, the β-turn structure found in VIP antagonist 1 was successfully reproduced by introducing the nonproteinogenic dipeptide isosters in the molecule, resulting in the development of peptidomimetic analogs.
	Of the various analogs tested, 8a showed good anticancer activity in the entire human cancer cell lines tested except HeP-G2 (liver cancer). It was the most promising analog in HeP-2 (laryngeal cancer), MiaPaCa.2 (pancreas), KB (oral) and ECV-304 (endothelial) cancer cell lines. In the ovarian cancer cell line PA-1, the smaller mimetic analog 10 showed maximum anti-cancer activity at 1 nM concentration whereas analog 8a showed similar inhibition of proliferation at 100 nM concentration. 

CHAPTER-III
The Total Synthesis of Conagenin
Conagenin (1), a low molecular weight immunomodulator, was isolated from the fermentation broth of Streptomyces roseosporus by Ishizuka and co-workers. It stimulates activated T cells, which produce lymphokines and generate antitumor effector cells. The antitumor efficacies of adriamycin and mitomycin C against murine leukemias are also enhanced by 1, making it a potential candidate for cancer chemotherapy.3 It has a densely functionalised structure consisting of a (2R,3S,4R)-2,4-dihydroxy-3-methylpentanoic acid moiety with three contiguous chiral centres, coupled to a (S)-α-methylserine possessing a quaternary chiral centre. 
Retrosynthetically, compound 1 can be obtained from the peptide coupling of two fragments 2 and 3. For the construction of both the fragments, 3-methyl-2-butene-1-ol 4 was used as a common starting material. In our synthesis, we could utilize the successful application, as a key step, of the method developed by our group for the synthesis of       2-methyl-1,3-diols via radical mediated regio and stereoselective ring opening of chiral trisubstituted 2,3-epoxy alcohols at the more substituted center using Cp2TiCl. 


           Scheme 1
Starting material for the synthesis of fragment 2 was syn epoxy alcohol 8 which was prepared from 4 in five steps. Benzylation of the hydroxyl group of 4 with BnBr, NaH and catalytic amount of TBAI gave compound 5 in 94% yield. SeO2-mediated allylic oxidation of compound 5 furnished aldehyde 6 in 63% yield.  Grignard addition to the aldehyde 6 with MeMgI gave racemic mixture 7, 7a in 84% yield. The racemic mixture was separated by Sharpless kinetic resolution to afford pure allylic alcohol 7 in 48% yield that was treated with mCPBA to get the requisite syn allylic alcohol 8 in 40% yield (Scheme 2). 


Scheme 2

The epoxy alcohol 8 on treatment with active titanium species Cp2TiCl in THF furnished the required all syn product 9 in 84% yield almost exclusively as a single isomer. The two secondary hydroxyl groups of 9 were protected with acetyls using Ac2O, Et3N and catalytic amount of DMAP to give 10 in 88% yield. Debenzylation of compound 10 using hydrogenation in the presence of catalytic amount of Pd/C in EtOAc gave primary hydroxyl intermediate that was converted to an acid 2, in 81% yield in three steps, using two step oxidation sequence (Scheme 3).


      Scheme 3

Fragment 3 was started from aldehyde 6 which was reduced to allylic alcohol 11 in 89% yield using NaBH4 in MeOH at 0 ºC (Scheme 4). Reaction of 12, prepared in 80% yield by the Katsuki-Sharpless catalytic asymmetric epoxidation of 11 using (–)-DIPT, with trichloroacetonitrile in the presence of a catalytic amount of DBU gave trichloroacetimidate 13 that underwent facile intramolecular SN2 opening of the epoxide ring by Et2AlCl to furnish the oxazole 14 in 84% yield in two steps. Acid hydrolysis of the oxazole ring 14 gave an amino diol that was protected in situ using Boc2O to furnish 15 in 92% yield. Compound 15 was subjected to hydrogenation using Pd/C as catalyst in EtOAc to give triol 16 in 94% yield. Selective oxidative cleavage of 1,2-diol moiety of 16 using NaIO4 resulted in the formation of an aldehyde which was oxidized to an acid and esterified using CH2N2 to give Boc-(S)-α-methylserine methyl ester 3 in 72% yield in three steps.

Scheme 4

The coupling of the fragments 2 and 3 was carried out using DCC, HOBt and DMAP to furnish the ester 17 in 91% yield. The ester intermediate was treated with acid followed by base treatment to get the protected conagenin 18 in 78% yield. Finally, saponification of 18 furnished the target molecule 1 in 83% yield (Scheme 5). Our synthetic conagenin showed a rotation value of [α]D = +50.2 (c 0.38, MeOH); lit. value: [α]D = +55.4 (c 4.6, MeOH).


Scheme 5
In conclusion, the total synthesis of this molecule not only provided an access to a larger quantity necessary for further biological studies, the scheme developed here can help to design and build more potent synthetic analogs.
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